

Cover Story
Clinical
Proven curative regimens containing platinum-based drugs—cisplatin and carboplatin—have become largely unavailable because of a nationwide drug shortage. The institutions that have some supplies of cisplatin and carboplatin are setting up algorithms for rationing their dwindling stocks, which usually means giving top priority to patients treated with curative intent and denying standard-of-care treatment to patients who cannot be cured but who can still benefit from these drugs.
In Brief


Clinical Roundup


Drugs & Targets
Trending Stories
- Trump backs off the 100% pharma tariffs ultimatum
- ASCO and Google Cloud set forth a vision for using AI to modernize health care and advance oncology
- KRAS pioneer and Stephenson Prize winner Frank McCormick aims to prevent all KRAS cancers with a pill
- White House announces “TrumpRx,” a new prescription drug website
- The Directors: Steven Artandi and Eric Winer on how looming policy changes “reverberate” through oncology
“Even when funding gets restored and if the H-1B visa threat doesn’t materialize, it creates an environment where especially young people become uncertain.” - Lazarex Cancer Foundation set to close its doors Dec. 31
Can health nonprofits survive in the current environment?